Effect of low-dose Naltrexone versus placebo in the treatment of chronic plaque psoriasis

Effect of low-dose Naltrexone versus placebo in the treatment of chronic plaque psoriasis: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N301

Enrollment

154

Registered

2019-09-26

Start date

2019-10-12

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Intervention 1: Intervention group: Routine treatment as well as Naltrexone tablet 4.5 mg before sleep for 12 weeks. Intervention 2: Control group: Routine treatment as well as placebo tablet before s

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years, Chronic plaque psoriasis

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding, Addiction to opium, Renal or liver failure, History of convulsion, Severe mental disorder

Design outcomes

Primary

Measure	Time frame
Improvement of the clinical signs of psoriasis. Timepoint: 12 weeks after the intervention. Method of measurement: Using Psoriasis Area Severity Index (PASI).;The quality of life. Timepoint: 12 weeks after the intervention. Method of measurement: Using Dermatology Life Quality Index (DLQI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Pedram ALirezaei

Hamedan University of Medical Sciences

prc@umsha.ac.ir+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026